BC Innovations | Jul 18, 2019
Translation in Brief

What Excision needs to demonstrate before bringing CRISPR-HIV therapy to clinic

After the scientific team behind Excision showed that CRISPR can excise viral HIV DNA from mice genomes, NIAID Director Anthony Fauci cautioned that the therapy will need to prove itself on at least three fronts...
BC Innovations | Jul 18, 2019
Distillery Therapeutics

CRISPR plus antiretroviral therapy could remove HIV virus from cells

DISEASE CATEGORY: Infectious INDICATION: HIV/AIDS Excision BioTherapeutics Inc. plans to enter the clinic with a CRISPR-based therapy it licensed from Temple University after co-founder Kamel Khalili showed it could remove integrated HIV virus along with...
BioCentury | Feb 23, 2018
Emerging Company Profile

Cutting viruses

Armed with a suite of CRISPR nucleases and multiple guide RNAs, Excision BioTherapeutics Inc. is using gene editing to cut out integrated latent viruses from host genomes. The newco is starting with HIV, but has...
BC Week In Review | Nov 17, 2017
Company News

Excision licenses new CRISPR IP from Berkeley

Excision BioTherapeutics Inc. (Philadelphia, Pa.) obtained exclusive licenses to IP from University of California Berkeley covering new CRISPR-based gene editing technologies. The licenses include the use of CRISPR systems using CRISPR-associated protein X (Cas X),...
BC Extra | Nov 13, 2017
Company News

Excision licenses new CRISPR IP

Excision BioTherapeutics Inc. (Philadelphia, Pa.) obtained exclusive licenses to IP from University of California Berkeley covering new CRISPR-based gene editing technologies. The licenses include the use of CRISPR systems using CasX, CasY and ARMAN endonucleases...
BC Week In Review | Sep 8, 2017
Financial News

Excision raises $10M seed round

On Sept. 6, gene editing company Excision BioTherapeutics Inc. (Philadelphia, Pa.) raised $10 million in a seed round led by Artis Ventures. Other undisclosed investors also participated. Excision is developing therapeutics to treat viral infectious...
BC Extra | Sep 6, 2017
Financial News

Excision raises $10M seed round

Gene editing company Excision BioTherapeutics Inc. (Philadelphia, Pa.) raised $10 million in a seed round led by Artis Ventures. Other undisclosed investors also participated. Excision is developing therapeutics to treat viral infectious diseases by utilizing...
BioCentury | Jan 13, 2017
Emerging Company Profile

Seeking viral strongholds

Agenovir Corp. is using CRISPR-based gene editing to eliminate latent viruses. Its lead program will test in vivo delivery of CRISPR-Cas9 components to treat persistent human papillomavirus infection. Viruses that remain dormant within cells for...
Items per page:
1 - 8 of 8